diagnostics Review Nuclear Imaging for the Diagnosis of Cardiac Amyloidosis in 2021 Weijia Li 1,*, Dipan Uppal 1, Yu Chiang Wang 1 , Xiaobo Xu 1, Damianos G. Kokkinidis 2, Mark I. Travin 3 and James M. Tauras 4 1 Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, 1400 Pelham Parkway South, Bronx, NY 10461, USA;
[email protected] (D.U.);
[email protected] (Y.C.W.);
[email protected] (X.X.) 2 Section of Cardiovascular Medicine, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA;
[email protected] 3 Department of Radiology, Division of Nuclear Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, 111 East 210th Street, Bronx, NY 10467, USA; mtravin@montefiore.org 4 Department of Medicine, Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, 111 East 210th Street, Bronx, NY 10467, USA; jtauras@montefiore.org * Correspondence:
[email protected] Abstract: Cardiac amyloidosis is caused by the deposition of misfolded protein fibrils into the extracellular space of the heart. The diagnosis of cardiac amyloidosis remains challenging because of the heterogeneous manifestations of the disease. There are many different types of amyloidosis with light-chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis being the most common types of cardiac amyloidosis. Endomyocardial biopsy is considered the gold standard for diagnosing cardiac amyloidosis and differentiating amyloid subtypes, but its use is limited because of the invasive nature of the procedure, with risks for complications and the need for specialized training and centers Citation: Li, W.; Uppal, D.; Wang, to perform the procedure.